Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, clinical trials, adult, Lymphomas, Clinical Research, Diseases, aggressive lymphoma, Lymphoid Malignancies, Study Population, Human
Methods: All patients within the PETRA database with newly diagnosed DLBCL, who were treated with R-CHOP and had available clinical data, baseline PET and i-PET scans were included.
The optimal transformation of Dmaxbulk, SUVpeak and ΔSUVmax was determined by choosing the best fitting Cox regression model with 3-year PFS as outcome, with highest R2 and lowest Akaike Information Criterion (AIC), while the cross-validated c-index was obtained as a measure for discrimination.
Subsequently, risk models were developed using clinical, baseline PET and i-PET data. The best risk model was compared to the IMPI model and our subsequent ClinicalPET model, also incorporating radiomic features (MTV, IPI, age, SUVpeak and Dmaxbulk) by determination of risk re-classification rates and by generating kaplan-meier (KM)-curves based on 60-30-10 PFS risk groups.
Results: 1014 patients were included in the analyses. Adding i-PET reponse (ΔSUVmax) to the IMPI model markedly improved outcome prediction (AIC 3177.44, c-index 0.72) and was superior to IMPI model alone (AIC 3247.09, c-index 0.68). By adding Dmaxbulk outcome prediction was further improved (AIC 3143.23, c-index 0.74), while SUVpeak did not show significant impact on outcome (p=0.07). Compared to the IMPI and the ClinicalPET model, the new model combining baseline features (MTV, age and Dmaxbulk) with i-PET reponse (ΔSUVmax) led to a sharper segregation of KM-curves with an improved rate of correct progression risk classification (22%; 95% confidence interval 12.1-31.1%).
Conclusions: Adding i-PET reponse to baseline clinical and PET parameters optimizes risk classification in DLBCL enabling individualized risk assessment in early phase of frontline treatment and outperforms our previous IMPI model and ClinicalPET models.
Disclosures: Zucca: Kite, A Gilead Company: Other: Travel Grant; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Miltenyi Biomedicine: Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Ipsen: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Eli/Lilly: Membership on an entity's Board of Directors or advisory committees; Curis: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Research Funding.
See more of: Oral and Poster Abstracts